Eisai CoESALF 69 Return-on-Tangible-Asset is -1.14% as of Mar. 2026. GuruFocus rates ESALF with a GF Score™ of 69/100 and a GF Value™ of $35.00 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Eisai Co ranks better than 51.84% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Eisai Co's annualizedNet Income for the quarter that ended in Mar. 2026 was $-82 Mil. Eisai Co's average total tangible assets for the quarter that ended in Mar. 2026 was $7,198 Mil. Therefore, Eisai Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -1.14%.
The historical rank and industry rank for Eisai Co's Return-on-Tangible-Asset or its related term are showing as below:
ESALF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.47 Med: 5.46 Max: 15.33
Current: 3.47
During the past 13 years, Eisai Co's highest Return-on-Tangible-Asset was 15.33%. The lowest was 3.47%. And the median was 5.46%.
ESALF's Return-on-Tangible-Asset is ranked better than 51.84% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs ESALF: 3.47
Eisai Co (OTCPK:ESALF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Eisai Co Return-on-Tangible-Asset Related Terms
Eisai Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Eisai Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESALF vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Eisai Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -1.14% mean?
Eisai Co (ESALF) has a Return-on-Tangible-Asset of -1.14% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Eisai Co and its competitors. Over the past decade, Eisai Co's Return-on-Tangible-Asset has ranged from 3.47 to 15.33. According to the industry distribution chart, Eisai Co ranks #484 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 48.2%.
Is Eisai Co's Return-on-Tangible-Asset too high?
Eisai Co's current Return-on-Tangible-Asset is -1.14%. Over the past 10 years, this metric has ranged from a low of 3.47 to a high of 15.33. Based on the distribution chart, Eisai Co ranks #484 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eisai Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #484 out of 1005 companies for Return-on-Tangible-Asset. This puts Eisai Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Historically, Eisai Co's own Return-on-Tangible-Asset has ranged from 3.47 to 15.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current Return-on-Tangible-Asset is -1.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $35.00, compared to a current price of $25.00 — trading 28.6% below its estimated fair value. The current Return-on-Tangible-Asset is -1.14%. Eisai Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Eisai Co (ESALF), the current Return-on-Tangible-Asset is -1.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $25.00 is trading 28.6% below its estimated GF Value™ of $35.00.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for ESALF:
Return-on-Tangible-Asset: -1.14%
GF Value™: $35.00 vs. price of $25.00 (28.6% below fair value)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for ESALF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
